Kornimate/medical-research-clean huggingface dataset:
study of calgranulin a/b levels in patients with newly diagnosed stage i,ii,iii breast cancer

Conditions: Breast Cancer

Summary: rationale: measuring levels of calgranulin a and calgranulin b in the blood of patients with breast cancer in the laboratory may help doctors identify and learn more about biomarkers related to breast cancer. purpose: this laboratory study is measuring calgranulin a and calgranulin b levels in the blood of patients with newly diagnosed stage i, stage ii, or stage iii breast cancer.

objectives: * determine circulating levels of calgranulin a and calgranulin b in patients with estrogen receptor negative or estrogen receptor positive, newly diagnosed, primary stage i-iii adenocarcinoma of the breast. outline: this is a pilot study. patients undergo a blood draw following diagnosis of breast cancer to assess levels of circulating tumor markers, calgranulin a and calgranulin b. serum samples are evaluated by enzyme-linked immunosorbent assay for tumor marker expression. projected accrual: a total of 60 patients will be accrued for this study.

Eligibility criteria:
disease characteristics: * histologically confirmed primary adenocarcinoma of the breast * stage i-iii disease * no evidence of metastatic disease * newly diagnosed disease * hormone receptor status: * estrogen receptor-positive- or -negative tumor patient characteristics: sex * not specified menopausal status * not specified performance status * not specified life expectancy * not specified hematopoietic * not specified hepatic * not specified renal * not specified other * not pregnant * no crohn's disease * no arthritis * no psoriasis * no lupus erythematosus * no multiple sclerosis * no other severe active inflammation * not c-reactive protein positive * no hiv positivity * no other serious medical or psychiatric illness prior concurrent therapy: radiotherapy * no prior radiotherapy for breast cancer surgery * no prior organ transplantation other * no prior systemic therapy for breast cancer

Keywords: stage i breast cancer stage ii breast cancer stage iiia breast cancer stage iiib breast cancer stage iiic breast cancer
obesity and clinical presentation of hyperandrogenism

Conditions: Polycystic Ovary Syndrome

Summary: polycystic ovarian syndrome (pcos) is the most common endocrine disorder in reproductive women. it is estimated that 5 to 10% of women of reproductive age have pcos. one of the major diagnostic criteria of pcos was chronic anovulation which lead to irregular menstruation, amenorrhea, and infertility; the other diagnostic criteria was hyperandrogenism which lead to hirsutism, acne and alopecia. furthermore, pcos is thought as a metabolic disorder, the long-term consequence of pcos were diabetes mellitus and cardiovascular disease, which are potentially dangerous in women health. early diagnosis and prevention is very important to the pcos patients. obesity is the most potential risk of threat to health of populations. there is a major impact of obesity on the pcos related disorders. insulin resistance and distribution of adipose tissue were thought to be the important risk factors of cardiovascular and metabolic syndrome. to treat pcos patients properly,wan-fang hospital had established a specific medical team. the investigators recently published in "fertility and sterility" about the clinical presentation of androgen excess in taiwanese women. hirsutism is much less prevalence (30%) in taiwanese pcos women than that previous reported (65-80%) in thewestern women. it is important to know that some clinical presentation of pcos might have ethic variance. insulin resistance was reported as another candidate that might have ethic variance. the investigators had reported about 40% women in pcos women were obese, it is similar with previous literature reported. obesity is a major factor that could be controlled during the treatment of pcos.weight reduction is one of our methods in pcos treatment. the progressive results for obese pcos women would be facing the risks of diabetes and metabolic syndrome. the investigators thought like to evaluate the benefit of weight reduction program to the prognosis of obese women with pcos. furthermore, it is known that endothelial progenitor cells (epc) be an early marker of cardiovascular disease, the investigators would like to know the role of epc to predict metabolic syndrome in women with pcos. wan-fang hospital has a professional team in pcos treatment and research which including gynecological endocrinologist, cardiologist, medical endocrinologist, specialist in weight reduction. this team had been working well for more that 4 years. the investigators hope that we can make a contribution to the study and treatment of pcos in taiwan.


Eligibility criteria:
inclusion criteria: * acne and/or hirsutism exclusion criteria: * male * menopause * tumor

Keywords: pcos acne hirsutism
the effects of virtual reality based exercises in patients with adhesive capsulitis

Conditions: Pain; Quality of Life; Range of Motion; Virtual Reality

Summary: musculoskeletal disorders such as adhesive capsulitis (ac) affect tissues such as muscles, bones, joints, tendons and ligaments and are the second most disabling condition worldwide. musculoskeletal systemic disorders are typically characterized by pain, limitations in joint range of motion or functional ability. existing studies have shown that virtual reality (vr) is beneficial in pain management for example; pain relief during dressing changes in burn patients. vr can also reduce anxiety, distract from the fear of pain, and reduce stress. it can distract the patients who are afraid of moving due to pain and enable them to move freely. in this study, ac patients will be treated with vr application. patients pain levels, upper extremity range of motion, functional activity levels and quality of life levels will be evaluated. a total of 36 patients will be included in the study. this observational randomized controlled study will contribute to the literature by investigating the effects of vr based exercises in individuals with ac.

individuals in the first group to be included in the study group will be included in a vr-based exercise program for half an hour a day, 5 days a week for a total of 4 weeks, in addition to routine electrotherapy programs for half an hour a day, 5 days a week for a total of 4 weeks. these individuals will use the oculus quest 2 vr system in the virtual environment thanks to the three-dimensional glasses and handpiece that can be worn on the head. they will play the registered games. these games will include purpose-oriented activities such as lying on the head and using bilaterally, which are intended to use the upper extremities of individuals with ac in daily life. participants will be treated under the constant supervision of a physiotherapist, will be rested at the end of the exercise, and will leave the clinic after making sure that there is no problem. individuals in the second group, who will be included in the traditional exercise group, will be included in the stretching and strengthening exercise program for half an hour a day, 5 days a week for a total of 4 weeks, for a total of 10 hours, in addition to the routine electrotherapy programs for half an hour a day, 5 days a week for a total of 4 weeks. the exercises will be performed by a physiotherapist working in the clinic and blind to the study. pain levels (visual analogue scale), upper extremity range of motion (goniometric measurement), functional activity levels (shoulder pain and disability index) and quality of life (sf-36) of all participants will be evaluated before and after the study.

Eligibility criteria:
inclusion criteria: * being between the ages of 18-65 * clinical diagnosis of adhesive capsulitis exclusion criteria: * inability to cooperate vr * surgery on the upper extremity or trunk * neurological disease
the pilot clinical study of pg2 injection on hemorrhagic stroke

Conditions: Hemorrhagic Stroke

Summary: astragalus membranaceus (am) is used to treat stroke for a long time, and a number of studies have shown that am can reduce cerebral infarction area and has anti-oxidation activity. pg2, a sterile powder of polysaccharides isolated from the root of astragulus (huang-chi) for intravenous injection, has been approved as a botanical drug by tfda. hemorrhagic stroke will induce secondary peri-blood clot edema and that may increase intracranial pressure to exacerbate clinical symptom. therefore, the purpose of the present study was to investigate the efficacy of pg2 on hemorrhagic stroke.

this will be a double-blind, randomized, placebo-controlled study. an estimated 60 (at least 48 evaluable) first hemorrhagic stroke patients will be randomly divided into the control and treatment groups. each group will be treated as follows: 1) control group will accept placebo t.i.w treatment for 14 days from second day of admission, in addition to standard ordinary treatment.; 2) treatment group will accept pg2 t.i.w treatment for 14 days from second day of admission, in addition to standard ordinary treatment. inflammatory index including the levels of c-reactive protein (crp), erythrocyte sedimentation rate (esr), s-100 protein, il-1, il-6, and tnf-beta levels will be measured and clinical symptoms including glasgow outcome scale (gos), modified rankin scale (mrs), functional independence measure (fim) and barthel index (bi) will be evaluated during this study.

Eligibility criteria:
inclusion criteria: * patients who confirmed diagnosis of first spontaneous hemorrhagic stroke * patients with hemorrhagic stroke in putamen * patients who admitted to the hospital within 24 hours of onset of hemorrhagic stroke * patients who signed the informed consent form exclusion criteria: * patient with hemorrhage in the area out of putamen or primary subarachnoid hemorrhage, arteriovenous malformation (avm) or brain tumor hemorrhage * patient who performed craniotomy * patient who suffering from cirrhosis, uremia with dialysis, bleeding tendency, severe cardiopulmonary disease or mental disorders would be unable to comply with the study by investigators' decision. * patients have enrolled or have not yet completed other investigational drug trials within 1 month before screening. * female patients are pregnant or breast-feeding.

Keywords: astragulus polysaccharides hemorrhagic stroke
value of platelet indices as predictive factor in thrombocytopenia

Conditions: Main Focus of the Study

Summary: platelets are essential blood component involved in primary hemostasis. a platelet count of less than 150 × 109/l is considered to be thrombocytopenia the causes of thrombocytopenia can be divided into two major groups, a decreased production of platelets or an under proliferative bm and an over-destruction of platelets. under proliferative bm defects most common cause is aplastic anemia, on the contrary, peripheral destruction of platelets may be as a result of an immune-mediated process namely immune thrombocytopenia (itp)

itp is a common auto-immune disease in which platelet count is reduced in peripheral blood leading to petechiae and hemorrhage. the platelet count is decreased because there are auto-antibodies in circulation against platelets that bind to platelets surface and destroy them in the spleen . aplastic anemia is characterized by suppression of bone marrow function resulting in progressive pancytopenia. the hematology analyzers can now give us certain parameters that can give information about platelets. these parameters are referred to as platelet indices in literature. platelet indices include mean platelet volume (mpv), platelet distribution width (pdw) and platelet large cell ratio (p-lcr) . they are sensitive, non-invasive, inexpensive biomarkers. mpv is the most commonly investigated platelet parameter, signifies the average size of platelets in the blood. pdw is a marker of platelet anisocytosis, which describes distribution of platelets produced by megakaryocytes and increases upon platelet activation. p-lcr is another marker of platelet activity, is a percentage of all platelets with a volume measuring over 12 fl circulating in the bloodstream .

Eligibility criteria:
inclusion criteria: * age more than 18 years old regardless of gender. * platelet count below 100000/cu mm. * confirmed diagnosis aplastic anaemia. * confirmed diagnosis immune thrombocytopenia exclusion criteria: * patient who received a platelet or blood transfusion within two weeks prior mpv analysis. * splenectomized patients * patients with chronic infection or inflammations. * diabetics and patients with coronary artery disease. * patients on anti- platelet or anti-inflammatory drugs.
development and evaluation of an online multidimensional musculoskeletal health programme

Conditions: Occupational Health

Summary: globally, work-related musculoskeletal symptoms (wrmss) have become one of the major public health issues, with musculoskeletal problems contributing to the largest proportion of lost work productivity. literature has reported that grassroots working-class workers (also known as low-skilled workers) are the most vulnerable group to wrmss as their work mostly exposes them to the identified risk factors. however, not many intervention studies have been conducted for low-skilled workers to prevent wrmss. based on the concept of the multidimensional approach from the literature, and the project team's previous evidence-based research results, this project will modify the project team's face-to-face evidence-based musculoskeletal health promotion program to an online mode with 4 weekly 45-minute workshops for low-skilled workers in the community under the covid-19 pandemic situation. thus, the project has the following specific objectives: (i) to determine the feasibility of conducting the proposed online program (ii) to examine the acceptability and satisfaction of the online program from the workers' perspectives (iii) to evaluate the potential effects of the online program on the primary outcomes: compliance with exercise regimes, improvement of musculoskeletal literacy, and reduction of the number of body parts with wrmss (iv) to evaluate the potential effects of the online program on the secondary outcomes: reduction of adverse workstyle, improvement of exercise self-efficacy, mental health, body mass index, hip-waist ratio, and blood pressure measurements


Eligibility criteria:
inclusion criteria: * low-skilled workers aged ≥ 18 * working full-time or part-time, * with at least one body part that had been affected by wrmss for at least one month. exclusion criteria: * engagement in wrms prevention programs in the workplace at the time of the study, * undergoing medical treatment
oral colchicine in men with castrate resistant prostate cancer

Conditions: Prostate Cancer

Summary: the purpose of this study is to determine the prostate specific antigen response to continuous low dose oral colchicine.

the investigators propose a simple phase ii trial of oral colchicine at the standard prophylactic dose utilized for gout in men with crpca who have failed taxotere based chemotherapy. the investigators will utilize a simple modified simon 2-stage design. the investigators plan to enroll 40 men for the study. the men should have completed prior taxotere based therapy or any other therapy post-taxotere including cabazitaxel one month prior to receipt of colchicine on trial. staging with a baseline bone scan, ct and psa as well as routine cbc, cmp and pap. the dose of the drug can be escalated as tolerated to a maximum of 1.2 mg bid. the patient would be seen at 21 day intervals. after every 3 cycles of treatment, patient would be restaged with ct and bone scan. patients with stable disease, partial response or complete response would continue therapy until either disease progression or intolerable toxicity after which the patient would be taken off study.

Eligibility criteria:
inclusion criteria: * castrate resistant prostate cancer * failure or intolerance of taxotere or cabazitaxel-based chemotherapy or abiraterone administered for castrate resistant prostate cancer is allowed * age \> 18 years and ability to provide informed consent * ecog performance status of 0, 1 or 2 * no prior use of colchicine within the last 2 years * no chemotherapy, hormonal therapy, immunotherapy or radiation therapy within 1 month of day 1, cycle 1 exclusion criteria: * inability to provide informed consent * hypersensitivity to colchicine * severe renal, gastrointestinal or hepatic disorders * pre-existing blood dyscrasia * plt \< 100k, anc \< 1000 * serum cr \> 2 x uln * bilirubin \> 2 uln * ast \> 2 x uln * concurrent use of cyp3a4 inhibitors which may increase drug levels and toxicity

Keywords: oral colchicine castrate-resistant prostate cancer failed taxotere based chemotherapy
sensitivity of multiparametric mri in differentiation between muscle invasive and non-muscle invasive urinary bladder cancer

Conditions: Cancer, Bladder

Summary: differentiation between non-muscle-invasive bladder cancer (nmibc) and muscle-invasive bladder cancer (mibc) is a cornerstone in the treatment plans.therefore, this study will try to evaluate the sensitivity and reliability of mpmri in accurate diagnosis of cancer bladder. primary objective: to detect the sensitivity of multiparametric mri in differentiation between muscle invasive and non-muscle invasive urinary bladder cancer in relation to the conventional cystoscopy and histopathological examination of the biopsy.


Eligibility criteria:
inclusion criteria: * all patients diagnosed with nmibc or mibc during diagnostic cystoscopy or by any radiologic investigation in the urology department of helwan university hospitals without being restricted to age or sex. * all histological types of bladder cancer * newly diagnosed, recurrent cases, or even patients undergoing follow-up cystoscopy. exclusion criteria: * patients with elevated renal function according to their age as this will be a contraindication to dce mri. * patients with absolute contraindication to mri (e.g.: metallic prosthesis). * patients with contraindication to undergo turbt (e.g.: unfit for surgery).

Keywords: cancer bladder multiparametric mri virads score
investigation of the effects of pilates training in parkinson patients

Conditions: Parkinson Disease; Pilates; Core Stability; Balance; Quality of Life

Summary: this study was planned to examine the effects of pilates training in parkinson's patients. the study included 34 parkinson's patients between hoehn \& yahr stage 1-2.5. pilates training was applied to the pilates group for 8 weeks, 3 days per week. to the control group; breathing exercises, active range of motion exercises and relaxation exercises were given as a home program 3 days per week for 8 weeks. it was concluded that pilates training performed to parkinson's patients 3 times a week for 8 weeks was effective on "core" stability, thickness of "core" muscles, functional exercise capacity, motor functions, freezing, fatigue and qol.

this study was planned to examine the effects of pilates training, which is a "core" stability based exercise method that improves body alignment, postural control and balance, on "core" stability, the thickness of the "core" muscles, functional exercise capacity, motor functions, freezing, fatigue and daily life activities (adls) in parkinson's patients. the study included 34 parkinson's patients between hoehn \& yahr stage 1-2.5. the patients were randomly divided into two groups as as pilates (n: 17) and control (n: 17). pilates training was applied to the pilates group for 8 weeks, 3 days per week. to the control group; breathing exercises, active range of motion exercises and relaxation exercises were given as a home program 3 days per week for 8 weeks. the "core" power with the "sit-ups" and the modified "push-ups" tests, the "core" endurans with lateral bridge, trunk flexor endurance and "prone bridge" tests, the thickness of the "core" muscles by ultrasonography, functional strength of the lower limbs with 5 times sit up test (5tsst), balance with the berg balance scale (bbs), functional mobility; with the timed up and go test (tug), functional exercise capacity and walking with the 6-minute walk test (6-mwt), motor impairment with the united parkinson's disease rating scale (updrs)-iii, freezing with freezing of gait questionnaire (fogq), fatigue with parkinson's fatigue scale (pfs-16), adls with updrs-ii, quality of life (qol) with parkinson's disease questionnaire-39 (pdq-39) were evaluated before and after treatment.

Eligibility criteria:
inclusion criteria: * after providing information about the research, agreeing to participate in the research * being 40 years or older * being diagnosed with '' idiopathic parkinson's disease '' by a specialist * to be between 1-2.5 values according to hoehn and yahr (h\&y) scale exclusion criteria: * standardized mini mental test score is less than 24 * presence of cardiovascular, pulmonary, orthopedic or other medical conditions that limit participation in pilates training

Keywords: parkinson disease pilates core stability balance quality of life
desensitising celiac disease patients with the human hookworm

Conditions: Celiac Disease

Summary: we have established that the hookworm necator americanus (na) dramatically alters the local and systemic immune landscape of the infected human host. consistent with the principle of desensitisation, diet managed celiac disease subjects previously infected by us with na will be invited to receive small incremental doses of gluten as pasta (3-25 mm straw of spaghetti) over 16 weeks. each participant will then be carefully re-assessed to determine if it is appropriate to undertake a 12-week gluten challenge.

hypothesis the adaptive th2/regulatory profile imposed by na will promote gluten tolerance following a micro-dose desensitising programme. primary aim: to determine the safety and efficacy of na as a tolerising agent in celiac subjects specific aim 1. undertake a therapeutic pilot study comparing mucosal histopathology before and after a gluten challenge, to be preceded by a programmed desensitising micro-challenge using na as a tolerising agent. specific aim 2. assess systemic and mucosal immune responses to gluten micro-challenge, na infection, and gluten re-challenge throughout the pilot study, to be referenced against hookworm-naive people with treated and untreated celiac disease. specific aim 3. utilising blood and tissue from hookworm-naive celiac disease volunteers, undertake in vitro studies focusing on the effects of na-derived excretory/secretory (es) products on gluten-stimulated gut mucosal cell apoptosis, cytokine and gene profiles.

Eligibility criteria:
inclusion criteria: * previously enrolled adults who received an experimental hookworm infection with diet treated celiac disease. exclusion criteria: * immune suppressive therapies

Keywords: celiac disease hookworm probiotic